H. Dietrich
No ORCID on file
· 7 papers in corpus
observational
2015
BACKGROUND: Concern and controversy characterize nowadays the use of hormone therapy for management of patients with menopausal complaints. This observational non-interventional study examined the use of a marketed oral formulation containi…
nonrandomized-trial
2006
OBJECTIVE: To examine the conception rate after cessation of a combination of 30 microg ethinyl E2 and 2 mg dienogest (EE/DNG). DESIGN: Prospective observational study. SETTING: Population-based cohort in Germany. PATIENT(S): Women who w…
observational
2000
The effects of Valette--an oral contraceptive containing ethinyloestradiol 0.03 mg and the antiandrogenic progestogen dienogest 2.0 mg--on the skin and hair were surveyed over 63,474 cycles in 10,718 women in routine gynaecological practice…
2000
SUMMARY The effects of Valette ® ‐ an oral contraceptive containing ethinyloestradiol 0.03 mg and the antiandrogenic progestogen dienogest 2.0 mg ‐ on the skin and hair were surveyed over 63,474 cycles in 10,718 women in routine gynaecologi…
1999
other
1999
OBJECTIVES AND METHODS: A postmarketing survey was carried out to determine the efficacy and tolerability of Valette (dienogest 2.0 mg and ethinylestradiol 0.03 mg) in routine gynecological practice. RESULTS: Valette had excellent contrace…
observational
1999
Objectives and methods A postmarketing survey was carried out to determine the efficacy and tolerability of Valette® (dienogest 2.0 mg and ethinylestradiol 0.03 mg) in routine gynecological practice.Results Valette had excellent contracepti…